Antibody-drug Conjugates In Top 10 of Medical Innovations For 2015
Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education, located in Cleveland, Ohio, earlier this week presented its 9th annual list of “Top 10 Medical Innovations” of up-and-coming technologies and drug therapies that are likely to have major breakthrough impact on healthcare and on improving patient care in 2015.
Sutro Collaborates with Merck and Recombinant Antibody Network
Earlier today, Sutro Biopharma, Inc, a biopharmaceutical company located in South San Francisco developing antibody drug conjugates and bispecific antibodies for targeted cancer therapies, and Merck Serono, the biopharmaceutical division of Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono, announced that they will collaborate in developing Antibody-drug Conjugates or ADCs.
Toxicology Study Demonstrates Decreased Mortality and Better Tolerability of ADC Generated with SMARTag Platform
Results of an in vivo toxicology study, demonstrates that an Antibody Drug Conjugate or ADC generated using the proprietary SMARTag™ platform has a better toxicity profile than a conventional ADC.
Danish Researchers Develop New Method for Efficient Tagging of Proteins
DNA linked to proteins, including antibodies, provides a strong partnership that can be used in diagnostic techniques, nanotechnology and other disciplines. DNA–protein conjugates, which tag proteins with DNA, can be used for the sensitive detection and visualisation of biological material. The method also provides easier access to handling proteins in nanotechnology, where the DNA acts as a handle on the protein.